Industries

Longevity and Anti-Aging Research

Longevity and anti-aging research investigates the molecular hallmarks of biological aging—genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, mitochondrial dysfunction, and cellular senescence—to develop interventions that extend healthy lifespan rather than merely postponing disease. Well-capitalized ventures such as Calico (Alphabet), Altos Labs, and Retro Biosciences are deploying billion-dollar programs in epigenetic reprogramming, while Unity Biotechnology and BioAge Labs advance senolytics through clinical trials. Academic researchers procure epigenomic profiling arrays, senescence-associated beta-galactosidase kits, mitochondrial respiration analyzers, NAD+ quantification assays, and longitudinal biomarker tracking platforms. The field is a major consumer of single-cell multi-omics, organoid models, and non-human primate resources. Regulatory pathways are evolving under the FDA geroscience initiative, and a growing number of institutional grants target healthspan rather than disease-specific endpoints, driving sustained demand for specialized research tools and biomarker platforms.

Details

Companies

Calico (Alphabet)Unity BiotechnologyAltos LabsRetro BiosciencesBioAge LabsJuvenescenceSierra Sciences

Market Size

$44 billion (2024, healthspan research market), projected $110 billion by 2030 at 16.5% CAGR

Target Researchers

Geroscientists, molecular biologists, translational aging researchers, epigenetics scientists, and clinical investigators studying biological aging mechanisms and healthspan extension.

Use Cases

Senolytic and senomorphic drug development targeting senescent cellsEpigenetic reprogramming for tissue rejuvenationNAD+ metabolism and mitochondrial aging studiesTelomere length dynamics measurement platformsBiological age clock validation and longitudinal cohort studiesProteostasis and autophagy pathway interventionsPlasma-based rejuvenation factor discovery